Current Report Filing (8-k)
March 25 2019 - 4:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 21,
2019
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
001-37861
|
|
93-0987903
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code:
(858) 259-9405
N/A
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [
]
ITEM
1.03
|
BANKRUPTCY OR RECEIVERSHIP.
|
On March 21, 2019, MabVax Therapeutics Holdings, Inc. (the
“Company”) filed a voluntary petition for
reorganization relief under Chapter 11 of Title 11 of the United
States Bankruptcy Code (the “Bankruptcy Code”) in the
United States Bankruptcy Court for the District of Delaware (the
“Bankruptcy Court”) (Case No. 19-10603 (CSS)). The
Company continues to manage and operate its business as a debtor in
possession pursuant to Bankruptcy Code Sections 1107 and 1108. The
Company intends to sell substantially all of its assets pursuant to
Section 363 of the Bankruptcy Code in the sixty days following the
filing of its Chapter 11 petition under a Bankruptcy Court
supervised sales process and, subject to sales proceeds and
remaining assets, could convert its case to Chapter 7, at which
point a Chapter 7 trustee will be appointed by the Bankruptcy
Court.
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS
|
(d)
Exhibits.
None.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this
report
to be signed on its
behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
MABVAX THERAPEUTICS HOLDINGS, INC.
|
|
|
|
|
Dated:
March 25, 2019
|
|
|
|
|
|
/s/ J. David
Hansen
|
|
|
|
|
|
|
J.
David Hansen
|
|
|
|
|
|
|
President and Chief Executive Officer
|